Table 2.
Clinical characteristics of pCR and non-pCR breast cancer patients.
| Characteristics | non-pCR Group(n= 75) | pCR Group (n= 39) | P Value |
|---|---|---|---|
| Age (y)* | 50.6 ± 10.7 | 48.8 ± 11.3 | 0.367 |
| Max tumour diameter (cm) | 3.99 ± 1.49 | 3.51 ± 1.57 | 0.112 |
| ER status | <0.001 | ||
| Negative | 12 (16.0) | 20 (51.3) | |
| Positive | 63 (84.0) | 19 (48.7) | |
| PR status | 0.029 | ||
| Negative | 11 (14.7) | 13 (33.3) | |
| Positive | 64 (85.3) | 26 (66.7) | |
| HER2 status | 0.042 | ||
| Negative | 52 (69.3) | 19 (48.7) | |
| Positive | 23 (30.7) | 20 (51.3) | |
| Ki-67 | 0.044 | ||
| Low | 19 (25.3) | 3 (7.7) | |
| High | 56 (74.7) | 36 (92.3) | |
| Tumour molecular type | 0.002 | ||
| Luminal A | 13 (17.3) | 1 (2.6) | |
| Luminal B | 54 (72) | 25 (64.1) | 0.595 |
| HER2 positive | 19 (35.2) | 11 (44.0) | |
| HER2 negative | 35 (64.8) | 14 (56.0) | |
| HER2 positive (Nonluminal) | 3 (4.0) | 9 (23.1) | |
| Triple-negative cancer | 5 (6.67) | 4 (10.3) |
Data represent the number of patients, and data in parentheses are percentages. *Data are ± standard deviations; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; Ki-67, antigen Ki67.